WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Elizabeth Doran, a retired Canadian woman, says she has had to pick up extra teaching shifts to afford her semaglutide medication Elizabeth Doran has been taking GLP-1 medications for nearly a year ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

US Supreme Court Backs Generic Drugmaker in 'Skinny Label' Patent Case By Blake Brittain WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication ...

Drugmaker Hikma’s generic version of Irish-American company Amarin Pharma’s cardiovascular medication Vascepa did not infringe ‌Amarin’s patents, the US supreme court ruled on Thursday in a decision ...

The controversial topic of authorized generics has been in the news again recently following a case in which Mylan Pharmaceuticals tried to sue the FDA for approving an authorized generic version of ...

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not ...

How many migrants live in South Africa, and what impact do they have on jobs and services? Official data and migration experts offer a reality check amid a heated national debate. A South African flag ...